Introducing CITIDARON®
How CITIDARON® works
When to use CITIDARON®?
Why use CITIDARON®?
How to use CITIDARON®?
CITIDARON® prescribing considerations
WHEN TO USE CITIDARON®?
- CITIDARON® should be used in smokers who are willing to stop smoking1
- From the outset of treatment, the goal should be the permanent cessation of the nicotine-containing products use1
- CITIDARON® can be prescribed as a first-line treatment option for smoking cessation
- Current treatment options have therapy cycles that range between 7 and 12 weeks. This is a significant time burden and may be a barrier to their use in certain patients2,3
- CITIDARON® offers patients a 25-day treatment period1 which patients may view as a manageable commitment when commencing their quitting journey
References
1. Citidaron Summary of Product Characteristics. Available at https://www.medicines.ie/medicines/citidaron-1-5-mg-tablets-35497/spc. Last accessed March 2025.
2. Zyban (bupropion) Summary of Product Characteristics. Available at https://assets.hpra.ie/products/Human/24440/Licence_PA1077-017-001_16042024135558.pdf. Accessed March 2025.
3. Champix (varenicline) Summary of Product Characteristics. Available at https://www.ema.europa.eu/en/documents/product-information/champixepar-product-information_en.pdf. Accessed March 2025.
Pharmacovigilance or Medical enquiries please contact:
E: drugsafety@consilienthealth.com
T: (01) 205 7766
All other queries: (01) 205 7760
Healthcare professionals are asked to report any suspected adverse reactions. To report an adverse event or a product complaint about a Consilient Health medicine, please contact Consilient Health at drugsafety@consilienthealth.com or 012057766. Adverse events and product complaints may also be reported to the Health Products Regulatory Authority. Reporting form and information can be found at http://www.hpra.ie then click on “report an issue”.
IE-CH-1561(1) Date of Preparation March 2025